Aclaris Therapeutics Inc Revenue Growth Rates (ACRS), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Aclaris Therapeutics Inc   (NASDAQ: ACRS)
 

ACRS's Revenue Growth by Quarter and Year

Aclaris Therapeutics Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/ACRS/growth
https://api.csimarket.com/api/v1/companies/ACRS/fundamentals
https://api.csimarket.com/api/v1/companies/ACRS/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
ACRS Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 1.48
2nd Quarter June 1.63
1st Quarter March 2.00
FY 5.11

ACRSs Annual Revenue
Aclaris Therapeutics Inc 's Revenue in the fiscal year 2025 $ 7.83 millions
Aclaris Therapeutics Inc 's Revenue in the fiscal year 2024 $ 18.72 millions
Aclaris Therapeutics Inc 's Revenue in the fiscal year 2023 $ 31.25 millions
Aclaris Therapeutics Inc 's Revenue in the fiscal year 2022 $ 29.75 millions
Aclaris Therapeutics Inc 's Revenue in the fiscal year 2021 $ 6.76 millions




ACRS Revenue third quarter 2026 Y/Y Growth Comment
Aclaris Therapeutics Inc reported drop in Revenue in the third quarter 2026 by -55.12% to $ 1.48 millions, from the same quarter in 2025.
The fall in the third quarter 2026 Aclaris Therapeutics Inc 's Revenue compares unfavorably to the Company's average Revenue jump of 64.73%.

Looking into third quarter 2026 results within Major Pharmaceutical Preparations industry 154 other companies have achieved higher Revenue growth. While Aclaris Therapeutics Inc ' s Revenue meltdown of -55.12% ranks overall at the positon no. 3339 in the third quarter 2026.


ACRS Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -55.12 %
2nd Quarter June -8.43 %
1st Quarter March 36.99 %
FY   -

Financial Statements
Aclaris Therapeutics Inc 's third quarter 2026 Revenue $ 1.48 millions ACRS's Income Statement
Aclaris Therapeutics Inc 's third quarter 2025 Revenue $ 3.30 millions Quarterly ACRS's Income Statement


ACRS Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -9.14 %
2nd Quarter June -18.5 %
1st Quarter March 53.85 %
FY (Year on Year)   -


Back to ACRS Growth rate Comparisons >> Back to ACRS Growth rate Comparisons >>


Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #155
Healthcare Sector #453
Overall #3339

Revenue Y/Y Growth Statistics
High Average Low
1046.35 % 64.73 % -85.94 %
(Jun 30 2023)   (Jun 30 2020)
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #155
Healthcare Sector #453
Overall #3339
Revenue Y/Y Growth Statistics
High Average Low
1046.35 % 64.73 % -85.94 %
(Jun 30 2023)   (Jun 30 2020)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Aclaris Therapeutics Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
1144.63 % 56.14 % -86.35 %
(Sep 30 2022)  


ACRS's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2026 Aclaris Therapeutics Inc disclosed drop in Revenue from the second quarter by -9.14% to $ 1.48 millions, from $ 1.63 millions achived in the previous reporting period.

Although periodic circumstance commonly energize III. Quarter 2026 Revenue, this plainly could not be substantial to rescue Major Pharmaceutical Preparations's company achievement, Most analysts pointed out.

Within Major Pharmaceutical Preparations industry 149 other companies have achieved higher Revenue quarter on quarter growth. While Aclaris Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 3216.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #150
Healthcare Sector #438
Overall #3216
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #150
Healthcare Sector #438
Overall #3216
Revenue Q/Q Growth Statistics
High Average Low
1144.63 % 56.14 % -86.35 %
(Sep 30 2022)  


ACRS's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2026 Aclaris Therapeutics Inc disclosed drop in Revenue from the second quarter by -9.14% to $ 1.48 millions, from $ 1.63 millions achived in the previous reporting period.

Although periodic circumstance commonly energize III. Quarter 2026 Revenue, this plainly could not be substantial to rescue Major Pharmaceutical Preparations's company achievement, Most analysts pointed out.

Within Major Pharmaceutical Preparations industry 149 other companies have achieved higher Revenue quarter on quarter growth. While Aclaris Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 3216.


Aclaris Therapeutics Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2026)		 12 Months Ending (Jun 30 2026) 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025)
Cumulative Revenue 12 Months Ending $ 6.40
Y / Y Revenue Growth (TTM) -59.34 %
Year on Year Revenue Growth Overall Ranking # 3613
Seqeuential Revenue Change (TTM) -22.12 %
Seq. Revenue Growth (TTM) Overall Ranking # 3017


Cumulative Revenue growth Comment
Aclaris Therapeutics Inc 's cumulative 12 months Revenue continue to drop, but on the faster rate at -59.34% year on year, at Sep 30 2026 compare to the -51.04% decrease at Jun 30 2026. If the Aclaris Therapeutics Inc 's fiscal year would end at Sep 30 2026, annual Revenue would be $6 millions.

In the Healthcare sector 495 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2998 to 3613.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 132
Healthcare Sector # 496
Overall # 3613

Revenue TTM Y/Y Growth Statistics
High Average Low
407.54 %
 39.23 %
-65.86 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 132
Sector # 415
S&P 500 # 3017
Cumulative Revenue growth Comment
Aclaris Therapeutics Inc 's cumulative 12 months Revenue continue to drop, but on the faster rate at -59.34% year on year, at Sep 30 2026 compare to the -51.04% decrease at Jun 30 2026. If the Aclaris Therapeutics Inc 's fiscal year would end at Sep 30 2026, annual Revenue would be $6 millions.

In the Healthcare sector 495 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2998 to 3613.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 132
Healthcare Sector # 496
Overall # 3613

Revenue TTM Y/Y Growth Statistics
High Average Low
407.54 %
39.23 %
-65.86 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 132
Sector # 415
S&P 500 # 3017




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
ACRS's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue drop for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Viatris Inc -0.28%$ -0.277 millions
Zoetis Inc -0.38%$ -0.375 millions
Pfizer Inc-0.43%$ -0.426 millions
Standard Biotools Inc -0.51%$ -0.508 millions
Lucid Diagnostics Inc -0.66%$ -0.661 millions
Globus Medical Inc -0.69%$ -0.693 millions
Conmed Corporation-0.70%$ -0.701 millions
Surgery Partners Inc -0.75%$ -0.755 millions
Myriad Genetics Inc -1.03%$ -1.025 millions
Lensar Inc -1.29%$ -1.292 millions
Fortrea Holdings Inc -1.40%$ -1.397 millions
Immunocore Holdings Plc-1.42%$ -1.419 millions
Pacira Biosciences inc -1.59%$ -1.595 millions
Organon and Co -1.75%$ -1.748 millions
Teva Pharmaceutical Industries Limited-1.90%$ -1.897 millions
Skinhealth Systems Inc -2.07%$ -2.071 millions
Charles River Laboratories International inc -2.20%$ -2.201 millions
Inogen Inc -2.40%$ -2.399 millions
Novavax inc -3.05%$ -3.048 millions
Seer Inc -3.14%$ -3.139 millions
Teladoc Health Inc -3.41%$ -3.406 millions
Scientific Industries Inc -3.50%$ -3.504 millions
Cg Oncology Inc -3.72%$ -3.721 millions
Treace Medical Concepts Inc -3.91%$ -3.905 millions
Sarepta Therapeutics Inc -4.51%$ -4.509 millions
Pacific Health Care Organization Inc-4.69%$ -4.689 millions
Tela Bio Inc -5.06%$ -5.058 millions
Perrigo Company Plc-5.22%$ -5.225 millions
Heron Therapeutics Inc -5.49%$ -5.493 millions
Milestone Scientific Inc -5.95%$ -5.948 millions


About Aclaris Therapeutics Inc Revenue Growth Rates (ACRS), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Aclaris Therapeutics Inc (CIK 1557746).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001104659-26-123374
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Aclaris Therapeutics Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.